Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Can-Fite’s CF101 Trial In Dry Eye Syndrome Fails To Meet Endpoints

Can-Fite CEO Pnina Fishman: The fact that the safety profile of CF101 remains high is encouraging.
Can-Fite BioPharma

CEO Pnina Fishman / Ilan Besor

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.

Can-Fite BioPharma Ltd. ( CANF ) announced today that the Phase 3 trial carried out by its subsidiary OphthaliX Inc. (OPLI.PK) of its drug CF101on patients with moderate-to-severe Dry Eye Syndrome was unsuccessful.

The trial did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary efficacy endpoints. CF101 was found to be well tolerated.

“We are disappointed from the fact that the phase 3 clinical trial for the treatment of Dry Eye Syndrome did not meet the endpoints. We intend to learn the trial results and extract from the clinical data received the lessons required for the successful advancement of Can-Fite’s compounds in various indications. The fact that the safety profile of CF101 remains high and is consistent is very encouraging and emphasizes an important advantage of CF101 compared to other drugs on the market. We believe in the platform technology and will continue to develop it for the appropriate indications, ” said Pnina Fishman, CEO of Can-Fite.

Last week, the company reported success in a Phase 2b trial of CF101 as a treatment for rheumatoid arthritis.

 

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News